Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Weight Management
Recent news which mentions Weight Management
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
December 24, 2024
Tags
LILLY DRN
Business
Health care policy
From
CNBC.com News
The weight-loss drug boom has become one of the internet's biggest scams
December 08, 2024
Tags
Cyber Report
Technology
LILLY DRN
From
CNBC.com News
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
December 05, 2024
Tags
Business
LILLY DRN
Biotech and Pharmaceuticals
From
CNBC.com News
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
December 04, 2024
Tags
Biotech and Pharmaceuticals
Novo Nordisk A/S
Business
From
CNBC.com News
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
October 24, 2024
Tags
Business
LILLY DRN
Alzheimer's disease
From
CNBC.com News
Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
September 12, 2024
Tags
Enterprise
Technology
Breaking News: Technology
From
CNBC.com News
If you invested $1,000 in drugmaker Eli Lilly 10 years ago, here's how much money you'd have now
August 08, 2024
Tags
Make It / Save and Invest
Make It / Money
Personal investing
From
CNBC.com News
This ETF is trying to satisfy appetites for weight loss stocks
July 06, 2024
Tags
Novo Nordisk A/S
stocks
Stock markets
From
CNBC.com News
Why half of all workers may struggle to get weight-loss drug health insurance coverage
May 30, 2024
Tags
Personnel
Small business
Small Business: Management
From
CNBC.com News
Weight loss drug Wegovy is now approved for heart health — but that won't mean broad insurance coverage just yet
March 16, 2024
Tags
CVS Health Corp
Health & Science
Biotechnology
From
CNBC.com News
The big health decisions Americans will need to make after starting new weight loss drugs
February 28, 2024
Tags
Weight loss diets
Diet and exercise
CNBC Changemakers
From
CNBC.com News
The pet drugs vets are now prescribing look a lot more like human medications
February 28, 2024
Tickers
CATS
DOGS
PETS
Tags
Health Insurance
Animals
Animal health
From
CNBC.com News
What you need to know about health insurance coverage for new weight loss drugs, and how to save on costs
February 16, 2024
Tags
Employee healthcare benefits
Corporate Finance
Employee benefits
From
CNBC.com News
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
February 10, 2024
Tags
Business News
Eli Lilly and Co
Amgen Inc
From
CNBC.com News
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
December 17, 2023
Tags
Weight management
Health care industry
Companies
From
CNBC.com News
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
December 01, 2023
Tags
Diabetes
Biotechnology
Clinical trials
From
CNBC.com News
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
November 02, 2023
Tags
Business
Breaking news
Earnings
From
CNBC.com News
As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data
October 24, 2023
Tags
Apple Inc
Health & Science
Abbott Laboratories
From
CNBC.com News
'Miracle drug' euphoria: Experts warn widespread use of weight loss medicine faces major hurdles
October 14, 2023
Tags
Breaking News: Markets
Breaking News: Investing
Investment strategy
From
CNBC.com News
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
October 10, 2023
Tickers
CEO
Tags
Novo Nordisk A/S
Biotech and Pharmaceuticals
Breaking News: Business
From
CNBC.com News
Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
September 27, 2023
Tags
Biotechnology
US: News
Health & Science
From
CNBC.com News
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here's what we know
September 10, 2023
Tags
Diabetes
Biotechnology
Addiction and substance abuse
From
CNBC.com News
Ozempic could be the next target of Medicare drug price negotiations – here's why
August 31, 2023
Tags
Politics
Business
Biotech and Pharmaceuticals
From
CNBC.com News
Weight loss drugs boost sales at retail pharmacies, but they may not help profits much
August 21, 2023
Tags
Weight management
Companies
Health care industry
From
CNBC.com News
Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says
August 16, 2023
Tags
Stroke
Heart attack
Weight loss diets
From
CNBC.com News
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
August 10, 2023
Tags
Business News
Obesity
Health care industry
From
CNBC.com News
Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data
August 09, 2023
Tags
Breaking news
Novo Nordisk A/S
Biotech and Pharmaceuticals
From
CNBC.com News
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
July 27, 2023
Tags
Business
Breaking news
Biotech and Pharmaceuticals
From
CNBC.com News
UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
July 26, 2023
Tags
Health care industry
Companies
Social issues
From
CNBC.com News
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
July 14, 2023
Tags
Novo Nordisk A/S
Biotech and Pharmaceuticals
Medication
From
CNBC.com News
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.